Back to search
Familial Hypercholesterolemia - Homozygous
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Familial Hypercholesterolemia - Homozygous trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Familial Hypercholesterolemia - Homozygous trials you may qualify forThis multicenter, randomized, placebo-controlled study will evaluate the efficacy and safety of zodasiran subcutaneous (SC) injection in subjects 12 years of ag…
This observational, multicenter, retrospective and prospective study aims to evaluate the impact of intensified lipid-lowering therapy including Evinacumab on c…
The purpose of this open-label, single arm, multicenter extension study is to evaluate the long-term safety and tolerability of inclisiran in participants with…
This repository will establish for the first time a system to carefully assess and monitor over time the general health and the amount of cholesterol in the art…
EDP167 is a double-stranded small interfering RNA (siRNA) drug targeting angiopoietin-like 3 protein (ANGPTL3), which may bring benefits for patients with dysli…
This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are refr…
Significant reduction in ANGPLT3 levels is expected to reduce plasma LDL-C and TG levels and may lead to the reduction of risk of coronary heart disease and car…
Homozygous familial hypercholesterolemia is a rare inherited disease of metabolism. It occurs in less than 1 in 1 million people within the United States. Patie…
The objective of this study is to evaluate the long-term safety of Leqvio in patients with familial hypercholesterolaemia or hypercholesterolaemia in post-marke…